Peptilogics
Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using AI-driven design, with lead program PLG0206 in a pivotal Phase 2/3 trial for prosthetic joint infections — an indication with no approved therapeutics.
- Company typePrivate
- Founded2013
- HeadquartersPittsburgh, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Peptilogics does
Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics for medical device-related infections, with its lead program PLG0206 (zaloganan) — a first-in-class engineered anti-biofilm peptide — currently enrolling patients in the pivotal Phase 2/3 RETAIN trial for the treatment of periprosthetic joint infection (PJI). The company targets an indication with no approved therapeutics, addressing approximately 45,000 U.S. cases annually where current standard-of-care failure rates reach 40–60% and five-year mortality is 25%. PLG0206 has secured a triple-layered FDA designation stack (Orphan Drug, Fast Track, and Qualified Infectious Disease Product), and the RETAIN trial is planned to enroll up to 240 patients across up to 50 U.S. clinical sites.
The company's discovery engine is the Nautilus™ AI platform, which combines proprietary deep generative models, predictive models, and biophysical simulation for in silico multiparameter optimization of peptide sequences. Nautilus™ is operationally paired with purpose-built supercomputing (via a Cerebras CS-2/WSE-2 strategic partnership) and a custom peptide synthesizer that closes the design-synthesize-test-train loop with proprietary data generation. Beyond PLG0206, Peptilogics has preclinical programs including PLG0301 for cystic fibrosis lung infections and AI-driven co-discovery collaborations with Orion Biotechnology (GPCR targets) and EpiAxis Therapeutics (epigenetic oncology).
Commercially, Peptilogics has no current revenue and is funded through equity and grant capital, most recently closing an oversubscribed $78 million Series B2 in October 2025 led by Presight Capital, Founders Fund, and Thiel Bio. Upon FDA approval, PLG0206 is expected to be distributed through U.S. hospital purchasing and specialty pharmacy channels targeting orthopedic and infectious disease departments. The company is led by founder/CEO Jonathan Steckbeck with a leadership team that combines anti-infective drug development, orthopedic device commercialization, HPC/AI, and large-pharma business development expertise.
Peptilogics firmographics
Firmographics- Name
- Peptilogics
- Legal name
- Peptilogics, Inc.
- Website
- https://peptilogics.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using AI-driven design, with lead program PLG0206 in a pivotal Phase 2/3 trial for prosthetic joint infections — an indication with no approved therapeutics.
- Ownership category
- akta.pro rank
Peptilogics industry classification
Industry- Product category
- Peptide Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Peptilogics is headquartered
LocationHeadquarters
- HQ city
- Pittsburgh
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Peptilogics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Peptilogics is a clinical-stage biotechnology company with no current revenue. The company is developing peptide therapeutics for medical device-related infections with PLG0206 (zaloganan) in Phase 2/3 trials. Revenue will be generated through eventual commercialization of approved drug products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Peptilogics product offering
Product offeringCore offering
Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using its proprietary Nautilus™ AI-powered computational design platform combined with purpose-built supercomputing. Its lead clinical asset, PLG0206 (zaloganan), is a first-in-class anti-biofilm engineered peptide therapeutic designed to cure and prevent medical device-related infections, specifically prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. The company is also advancing preclinical pipeline programs including PLG0301 for cystic fibrosis lung infections.
Product overview
Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug platform. The company's clinical stage pipeline is led by PLG0206 (also called zaloganan), a first-in-class engineered antimicrobial peptide therapeutic for treating prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. Supporting the therapeutic pipeline is the Nautilus™ AI platform, a computational drug discovery system that enables rapid peptide design and optimization through deep learning models and purpose-built supercomputing. The company also has preclinical programs including PLG0301 for cystic fibrosis lung infections.
Differentiator
Problem solved
Functional benefit
Products and services
- PLG0206 (Zaloganan) First-in-class engineered cationic antibacterial peptide therapeutic targeting and disrupting bacterial membranes within biofilms; designed to cure and prevent prosthetic joint infections (PJI) and other medical device-related infections. Has received FDA Orphan Drug Designation, Fast Track Designation, and Qualified Infectious Disease Product (QIDP) status. Currently enrolling Phase 2/3 RETAIN pivotal trial.
- Nautilus™ AI Discovery Platform Proprietary AI-powered computational platform enabling in silico predictive peptide design across diverse targets. Combines deep generative models, predictive AI models, and biophysical simulation for multiparameter optimization of peptide sequences with drug-like properties (safety, efficacy, synthesizability, IP). Accelerated up to 1000x via purpose-built on-prem supercomputing and strategic Cerebras Systems partnership. Leveraged for internal pipeline and external co-discovery collaborations.
Quantifiable outcome
- 4-log10 mean bacterial reduction in explanted prosthetic joints exposed to PLG0206
- +3 more outcomes
Companies that use Peptilogics
Customer profileSegments1 record
Ideal customer profiles2 records
Peptilogics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Peptilogics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered strategic and core.
- EpiAxis TherapeuticsstrategicStrategic drug discovery partnership leveraging Peptilogics' AI platform for lead optimization against epigenetic oncology targets. Focus on reprogramming cancer cells and immune reinvigoration for metastatic breast cancer treatment.
- Orion BiotechnologystrategicAI-driven drug discovery collaboration targeting undrugged GPCR (G protein-coupled receptor) targets. Combines Peptilogics' Nautilus™ AI platform with Orion Biotechnology's proprietary receptor-ligand shape space exploration platform for precision-engineered peptides.
- Cerebras SystemscoreStrategic partnership leveraging Cerebras CS-2 system powered by the world's fastest AI processor (WSE-2) to accelerate peptide drug design. Peptilogics uses Cerebras' AI compute to run advanced deep learning models for novel peptide therapeutics discovery, potentially reducing training time by up to 1000x.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Peptilogics competitors and assessment
Company assessmentDirect peers
- Schrödinger: Computational drug discovery company using physics-based simulation and machine learning to design therapeutics, both for its own pipeline and through partnerships. Directly comparable to Peptilogics' AI-driven, in silico design approach to novel therapeutic candidates.
- Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company developing oral and injectable peptide candidates for endocrine diseases and rare conditions. Comparable in modality (synthetic peptides) and in using rational engineering to develop differentiated, drug-like peptide therapeutics.
- Zealand Pharma: Clinical- and commercial-stage peptide therapeutics company developing engineered peptides across metabolic and specialty indications. Comparable as a peptide-focused biotech using rational design to generate drug-like peptide candidates.
- Iterum Therapeutics: Clinical-stage anti-infective company developing antibiotics (e.g., sulopenem) for drug-resistant infections including complicated urinary tract and intra-abdominal infections. Directly comparable as a small, focused anti-infective biotech pursuing regulatory differentiation against resistant pathogens.
- Theravance Biopharma: Clinical-stage biopharma developing therapies with a focus on infectious disease and respiratory conditions, including antibiotic candidates. Comparable as a small-cap anti-infective biotech pursuing differentiated therapies against resistant pathogens.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable in its use of a proprietary computational platform to systematically generate drug candidates across multiple indications.
- ContraFect Corporation: Was a clinical-stage anti-infective biotech developing direct lytic agents (lysins) and other novel therapies for drug-resistant bacterial infections. Comparable to Peptilogics in its focus on first-in-class anti-infective mechanisms targeting biofilm and resistant pathogens (though it has since undergone significant restructuring).
Broad incumbents
- AbCellera Biologics: AI-powered antibody discovery platform company with a much larger partnership-driven business and broader biologic focus. Comparable in its use of AI/ML and high-throughput data infrastructure to accelerate biologic candidate generation, though focused on antibodies rather than antimicrobial peptides.
Emerging players
- Xaira Therapeutics: AI-native drug discovery company founded to apply frontier AI models to therapeutic discovery across multiple modalities and indications. Comparable as an emerging AI-driven biotech applying large-scale compute and generative models to expand addressable drug design space.
- Insitro: AI-driven drug discovery company using machine learning on large-scale biological data to identify novel therapeutics. Comparable in combining proprietary AI platforms with biological experimentation to discover differentiated drug candidates, though focused on small molecules and rare diseases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Peptilogics social profiles
Digital presencePeptilogics compliance and trust
Trust signalCompliance2 records
Peptilogics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Peptilogics leadership team
Management profileNumber of profiles
Profiles14 records
Peptilogics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Peptilogics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Peptilogics
What does Peptilogics do?
Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using its proprietary Nautilus™ AI-powered computational design platform combined with purpose-built supercomputing. Its lead clinical asset, PLG0206 (zaloganan), is a first-in-class anti-biofilm engineered peptide therapeutic designed to cure and prevent medical device-related infections, specifically prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. The company is also advancing preclinical pipeline programs including PLG0301 for cystic fibrosis lung infections.
Is Peptilogics a public or private company?
Peptilogics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Peptilogics founded?
Peptilogics was founded in 2013. It employs 11 to 50 people.
Where is Peptilogics based?
Peptilogics is headquartered in Pittsburgh, United States, in the North America region.
How does Peptilogics make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Peptilogics's main competitors?
Direct peers on record are Schrödinger, Crinetics Pharmaceuticals, Zealand Pharma, Iterum Therapeutics, Theravance Biopharma, Recursion Pharmaceuticals and ContraFect Corporation. AbCellera Biologics is listed as a broad incumbent. Emerging players are Xaira Therapeutics and Insitro.
Does Peptilogics have an API?
No public API is recorded for Peptilogics.
What industry is Peptilogics in?
Peptilogics's product category is Peptide Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.